{"id":5027,"date":"2025-11-03T18:58:47","date_gmt":"2025-11-03T15:58:47","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5027"},"modified":"2025-11-03T19:01:49","modified_gmt":"2025-11-03T16:01:49","slug":"biologics-license-application-bla","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/biologics-license-application-bla\/","title":{"rendered":"Biyolojik Lisans Ba\u015fvurusu (BLA): FDA Onay S\u00fcrecine \u0130li\u015fkin Eksiksiz Bir K\u0131lavuz"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><strong>Biyolojik Lisans Ba\u015fvurusu (BLA), Duchenne Musk\u00fcler Distrofi (DMD) hastalar\u0131na yeni biyolojik tedavilerin ula\u015ft\u0131r\u0131lmas\u0131nda kritik bir rol oynamaktad\u0131r.<\/strong> BLA, bir biyoteknoloji veya ila\u00e7 \u015firketinin biyolojik bir \u00fcr\u00fcn\u00fc pazarlamak i\u00e7in onay almak \u00fczere ABD G\u0131da ve \u0130la\u00e7 Dairesi&#039;ne (FDA) yapt\u0131\u011f\u0131 resmi ba\u015fvurudur. Gen terapileri, ekzon atlama ila\u00e7lar\u0131 ve monoklonal antikorlar gibi son teknoloji tedavilerin h\u0131zla ilerledi\u011fi Duchenne ba\u011flam\u0131nda, BLA s\u00fcrecini anlamak \u00e7ok \u00f6nemlidir. Bu s\u00fcre\u00e7, umut vadeden tedavilerin hastalara ula\u015fmadan \u00f6nce g\u00fcvenlik, etkinlik ve kalite a\u00e7\u0131s\u0131ndan kat\u0131 standartlar\u0131 kar\u015f\u0131lamas\u0131n\u0131 sa\u011flar.<\/p>\n\n\n\n<div class=\"wp-block-rank-math-toc-block\" id=\"rank-math-toc\"><h2>\u0130\u00e7indekiler<\/h2><nav><ul><li><a href=\"#what-is-a-biologics-license-application-bla\">Biyolojik Lisans Ba\u015fvurusu (BLA) Nedir?<\/a><\/li><li><a href=\"#why-is-a-bla-important\">BLA Neden \u00d6nemlidir?<\/a><\/li><li><a href=\"#key-components-of-a-biologics-license-application\">Biyolojik Lisans Ba\u015fvurusunun Temel Bile\u015fenleri<\/a><\/li><li><a href=\"#the-bla-review-and-approval-process\">BLA \u0130nceleme ve Onay S\u00fcreci<\/a><\/li><li><a href=\"#bla-vs-nda-whats-the-difference\">BLA ve NDA Aras\u0131ndaki Fark Nedir?<\/a><\/li><li><a href=\"#electronic-bla-e-bla-submissions\">Elektronik BLA (eBLA) G\u00f6nderimleri<\/a><\/li><li><a href=\"#bla-supplements-and-amendments\">BLA Ekleri ve De\u011fi\u015fiklikleri<\/a><\/li><li><a href=\"#tips-for-a-successful-bla-submission\">Ba\u015far\u0131l\u0131 Bir BLA Ba\u015fvurusu \u0130\u00e7in \u0130pu\u00e7lar\u0131<\/a><\/li><li><a href=\"#fa-qs-about-bl-as\">BLA&#039;lar Hakk\u0131nda SSS<\/a><ul><li><a href=\"#faq-question-1762183238646\">FDA&#039;deki BLA&#039;lar\u0131 kim inceliyor?<\/a><\/li><li><a href=\"#faq-question-1762183249315\">BLA incelemesi ne kadar s\u00fcrer?<\/a><\/li><li><a href=\"#faq-question-1762183275484\">BLA geri \u00e7ekilebilir mi?<\/a><\/li><li><a href=\"#faq-question-1762183285301\">BLA onay\u0131ndan sonra ne olur?<\/a><\/li><\/ul><\/li><li><a href=\"#conclusion\">Sonu\u00e7<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"what-is-a-biologics-license-application-bla\"><strong>Biyolojik Lisans Ba\u015fvurusu (BLA) Nedir?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biyolojik \u00dcr\u00fcn Lisans Ba\u015fvurusu (BLA), Amerika Birle\u015fik Devletleri&#039;nde biyolojik bir \u00fcr\u00fcn\u00fcn pazarlanmas\u0131 i\u00e7in onay almak \u00fczere ABD G\u0131da ve \u0130la\u00e7 Dairesi&#039;ne (FDA) sunulan resmi bir taleptir. Bu ba\u015fvuru, Halk Sa\u011fl\u0131\u011f\u0131 Hizmetleri (PHS) Yasas\u0131 kapsam\u0131nda gereklidir ve a\u015f\u0131lar, monoklonal antikorlar, gen terapileri, h\u00fccresel terapiler ve rekombinant proteinler gibi biyolojik \u00fcr\u00fcnler i\u00e7in ge\u00e7erlidir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Basit\u00e7e ifade etmek gerekirse, BLA, biyolojik bir \u00fcr\u00fcn\u00fcn ama\u00e7lanan kullan\u0131m\u0131 i\u00e7in g\u00fcvenli, saf ve etkili oldu\u011funu ve mevcut \u0130yi \u00dcretim Uygulamalar\u0131 (cGMP) ile uyumlu olarak \u00fcretildi\u011fini g\u00f6sterir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"why-is-a-bla-important\"><strong>BLA Neden \u00d6nemlidir?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">BLA s\u00fcreci, piyasaya sunulan biyolojik \u00fcr\u00fcnlerin s\u0131k\u0131 g\u00fcvenlik ve kalite standartlar\u0131n\u0131 kar\u015f\u0131lamas\u0131n\u0131 sa\u011flamak i\u00e7in olmazsa olmazd\u0131r. Biyolojik ila\u00e7lar genellikle geleneksel k\u00fc\u00e7\u00fck molek\u00fcll\u00fc ila\u00e7lardan daha karma\u015f\u0131kt\u0131r ve \u00fcretim s\u00fcre\u00e7lerinde genellikle canl\u0131 h\u00fccreler veya organizmalar kullan\u0131l\u0131r. Bu karma\u015f\u0131kl\u0131k nedeniyle, BLA incelemesi genellikle Yeni \u0130la\u00e7 Ba\u015fvurusu (NDA) s\u00fcrecinden daha kapsaml\u0131d\u0131r.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ba\u015far\u0131l\u0131 bir BLA, \u015firketlerin \u015funlar\u0131 yapmas\u0131na olanak tan\u0131r:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Biyolojik \u00fcr\u00fcnlerini ABD&#039;de ticarile\u015ftirmek ve da\u011f\u0131tmak.<\/li>\n\n\n\n<li>Belirli bir s\u00fcre i\u00e7in pazarda m\u00fcnhas\u0131rl\u0131k kazanmak.<\/li>\n\n\n\n<li>Yat\u0131r\u0131mc\u0131lar, sa\u011fl\u0131k hizmeti sa\u011flay\u0131c\u0131lar\u0131 ve hastalar nezdinde g\u00fcvenilirlik olu\u015fturmak.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"key-components-of-a-biologics-license-application\"><strong>Biyolojik Lisans Ba\u015fvurusunun Temel Bile\u015fenleri<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Eksiksiz bir BLA sunumu, klinik \u00f6ncesi ve klinik geli\u015ftirme s\u0131ras\u0131nda \u00fcretilen \u00e7ok miktarda verinin yan\u0131 s\u0131ra \u00fcretim ve kalite kontrol ayr\u0131nt\u0131lar\u0131n\u0131 da i\u00e7erir. Ana bile\u015fenler \u015funlard\u0131r:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>\u0130dari Bilgiler<\/strong>\n<ul class=\"wp-block-list\">\n<li>Ba\u015fvuran\u0131n ad\u0131, adresi ve ileti\u015fim bilgileri<\/li>\n\n\n\n<li>\u00dcr\u00fcn ad\u0131 ve tescilli bilgiler<\/li>\n\n\n\n<li>Patent sertifikalar\u0131 ve etiketleme bilgileri<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Klinik \u00d6ncesi Veriler<\/strong>\n<ul class=\"wp-block-list\">\n<li>Klinik d\u0131\u015f\u0131 g\u00fcvenlik ve toksisite \u00e7al\u0131\u015fmalar\u0131<\/li>\n\n\n\n<li>Farmakoloji verileri ve etki mekanizmas\u0131<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Klinik Veriler<\/strong>\n<ul class=\"wp-block-list\">\n<li>Faz 1, 2 ve 3 klinik deney sonu\u00e7lar\u0131<\/li>\n\n\n\n<li>Etkinli\u011fi ve g\u00fcvenli\u011fi g\u00f6steren istatistiksel analizler<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Kimya, \u00dcretim ve Kontroller (CMC)<\/strong>\n<ul class=\"wp-block-list\">\n<li>\u00dcretim s\u00fcreci ve tesis detaylar\u0131<\/li>\n\n\n\n<li>Kalite g\u00fcvence ve test prosed\u00fcrleri<\/li>\n\n\n\n<li>Parti kay\u0131tlar\u0131, \u00f6zellikler ve do\u011frulama raporlar\u0131<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Etiketleme ve Paketleme<\/strong>\n<ul class=\"wp-block-list\">\n<li>\u00d6nerilen re\u00e7ete bilgileri<\/li>\n\n\n\n<li>Ambalaj tasar\u0131m\u0131 ve hasta bilgilendirme bro\u015f\u00fcrleri<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>\u00c7evre ve Tesis Bilgileri<\/strong>\n<ul class=\"wp-block-list\">\n<li>\u00c7evresel de\u011ferlendirmeler<\/li>\n\n\n\n<li>Denetim haz\u0131rl\u0131\u011f\u0131 dok\u00fcmantasyonu<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"the-bla-review-and-approval-process\"><strong>BLA \u0130nceleme ve Onay S\u00fcreci<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">FDA&#039;nin Biyolojik De\u011ferlendirme ve Ara\u015ft\u0131rma Merkezi (CBER) veya \u0130la\u00e7 De\u011ferlendirme ve Ara\u015ft\u0131rma Merkezi (CDER), \u00fcr\u00fcn t\u00fcr\u00fcne ba\u011fl\u0131 olarak BLA&#039;lar\u0131 inceler. S\u00fcre\u00e7 genellikle \u015fu a\u015famalar\u0131 izler:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>BLA \u00d6ncesi Toplant\u0131<\/strong><br>Sponsorlar, ba\u015fvuru haz\u0131rl\u0131\u011f\u0131n\u0131 g\u00f6r\u00fc\u015fmek ve d\u00fczenleyici beklentileri netle\u015ftirmek i\u00e7in FDA ile bir araya gelir.<\/li>\n\n\n\n<li><strong>BLA Sunumu ve Dosyalama \u0130ncelemesi<\/strong><br>FDA, ba\u015fvurunun detayl\u0131 de\u011ferlendirme i\u00e7in yeterince eksiksiz olup olmad\u0131\u011f\u0131n\u0131 belirlemek amac\u0131yla 60 g\u00fcnl\u00fck bir dosyalama incelemesi ger\u00e7ekle\u015ftirir.<\/li>\n\n\n\n<li><strong>Kapsaml\u0131 \u0130nceleme A\u015famas\u0131<\/strong><br>Kurum, klinik verileri, \u00fcretim bilgilerini ve etiketlemeyi inceler. \u00dcretim tesislerinde denetimler yap\u0131labilir.<\/li>\n\n\n\n<li><strong>Dan\u0131\u015fma Kurulu Toplant\u0131s\u0131 (e\u011fer varsa)<\/strong><br>Ba\u011f\u0131ms\u0131z uzmanlar ba\u015fvuruyu de\u011ferlendirip \u00f6nerilerde bulunabilirler.<\/li>\n\n\n\n<li><strong>FDA Karar\u0131<\/strong><br>FDA, giderilmesi gereken eksiklikleri \u00f6zetleyen bir onay mektubu veya Tam Yan\u0131t Mektubu (CRL) d\u00fczenler.<\/li>\n\n\n\n<li><strong>Onay Sonras\u0131 Taahh\u00fctler<\/strong><br>Sponsorlar\u0131n pazarlama sonras\u0131 \u00e7al\u0131\u015fmalar veya Faz 4 taahh\u00fctleri y\u00fcr\u00fctmesi gerekebilir.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bla-vs-nda-whats-the-difference\"><strong>BLA ve NDA Aras\u0131ndaki Fark Nedir?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Hem BLA&#039;lar hem de NDA&#039;lar FDA onay\u0131na giden yollard\u0131r ancak \u00fcr\u00fcn t\u00fcr\u00fcne g\u00f6re farkl\u0131l\u0131k g\u00f6sterirler:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><strong>Bak\u0131\u015f a\u00e7\u0131s\u0131<\/strong><\/th><th><strong>BLA (Biyolojikler)<\/strong><\/th><th><strong>NDA (\u0130la\u00e7lar)<\/strong><\/th><\/tr><\/thead><tbody><tr><td>D\u00fczenleyici Otorite<\/td><td>PHS Yasas\u0131<\/td><td>Federal G\u0131da, \u0130la\u00e7 ve Kozmetik Yasas\u0131<\/td><\/tr><tr><td>\u00dcr\u00fcn T\u00fcr\u00fc<\/td><td>Biyolojikler (proteinler, h\u00fccreler, a\u015f\u0131lar)<\/td><td>K\u00fc\u00e7\u00fck molek\u00fcll\u00fc ila\u00e7lar<\/td><\/tr><tr><td>\u0130nceleme B\u00f6l\u00fcm\u00fc<\/td><td>CBER veya CDER<\/td><td>CDER<\/td><\/tr><tr><td>Onay Odakl\u0131<\/td><td>G\u00fcvenlik, safl\u0131k ve g\u00fc\u00e7<\/td><td>G\u00fcvenlik ve etkinlik<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"electronic-bla-e-bla-submissions\"><strong>Elektronik BLA (eBLA) G\u00f6nderimleri<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">FDA, elektronik ba\u015fvurular\u0131n eCTD (Elektronik Ortak Teknik Belge) format\u0131nda kullan\u0131lmas\u0131n\u0131 te\u015fvik eder. Bu standart, t\u00fcm BLA bile\u015fenlerinde tutarl\u0131l\u0131k, izlenebilirlik ve inceleme kolayl\u0131\u011f\u0131 sa\u011flar.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">eBLA&#039;n\u0131n temel faydalar\u0131 \u015funlard\u0131r:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>FDA ile ak\u0131c\u0131 ileti\u015fim<\/li>\n\n\n\n<li>Azalt\u0131lm\u0131\u015f idari y\u00fck<\/li>\n\n\n\n<li>Daha h\u0131zl\u0131 inceleme zaman \u00e7izelgeleri<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"bla-supplements-and-amendments\"><strong>BLA Ekleri ve De\u011fi\u015fiklikleri<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Bir BLA onayland\u0131ktan sonra, \u00fcreticilerin onay sonras\u0131 de\u011fi\u015fiklikler yapmas\u0131 gerekebilir, \u00f6rne\u011fin:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Yeni endikasyonlar veya dozaj formlar\u0131<\/li>\n\n\n\n<li>\u00dcretim tesisi de\u011fi\u015fiklikleri<\/li>\n\n\n\n<li>Etiketleme g\u00fcncellemeleri<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Bu de\u011fi\u015fiklikler, \u00fcr\u00fcn kalitesi veya g\u00fcvenli\u011fi \u00fczerindeki etkilerine ba\u011fl\u0131 olarak ayr\u0131 ayr\u0131 incelenen BLA takviyelerini gerektirir.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"tips-for-a-successful-bla-submission\"><strong>Ba\u015far\u0131l\u0131 Bir BLA Ba\u015fvurusu \u0130\u00e7in \u0130pu\u00e7lar\u0131<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FDA ile Erken Etkile\u015fime Ge\u00e7in:<\/strong> BLA \u00f6ncesi toplant\u0131lar\u0131 planlay\u0131n ve beklentileri netle\u015ftirin.<\/li>\n\n\n\n<li><strong>Eksiksiz Dok\u00fcmantasyonu Koruyun:<\/strong> Klinik \u00f6ncesi, klinik ve \u00fcretim b\u00f6l\u00fcmlerinde veri b\u00fct\u00fcnl\u00fc\u011f\u00fcn\u00fc ve izlenebilirli\u011fini sa\u011flay\u0131n.<\/li>\n\n\n\n<li><strong>CMC Haz\u0131rl\u0131\u011f\u0131na Odaklanma:<\/strong> BLA gecikmelerinin en yayg\u0131n nedenleri aras\u0131nda \u00fcretim sorunlar\u0131 yer al\u0131yor.<\/li>\n\n\n\n<li><strong>Denetim Plan\u0131:<\/strong> Denetime haz\u0131r olun ve detayl\u0131 tesis ve parti kay\u0131tlar\u0131 tutun.<\/li>\n\n\n\n<li><strong>Kald\u0131ra\u00e7 D\u00fczenleme Dan\u0131\u015fmanlar\u0131:<\/strong> Deneyimli uzmanlar FDA gereklilikleri ve g\u00f6nderim n\u00fcanslar\u0131 konusunda size yard\u0131mc\u0131 olabilir.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"fa-qs-about-bl-as\"><strong>BLA&#039;lar Hakk\u0131nda SSS<\/strong><\/h2>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list\">\n<div id=\"faq-question-1762183238646\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">FDA&#039;deki BLA&#039;lar\u0131 kim inceliyor?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>BLA&#039;lar biyolojik maddenin t\u00fcr\u00fcne ve endikasyonuna ba\u011fl\u0131 olarak CBER veya CDER taraf\u0131ndan incelenir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1762183249315\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">BLA incelemesi ne kadar s\u00fcrer?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Standart inceleme s\u00fcresi 10 ayd\u0131r, \u00f6ncelikli incelemede ise bu s\u00fcre 6 aya kadar k\u0131salt\u0131labilir.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1762183275484\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">BLA geri \u00e7ekilebilir mi?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>Evet, sponsorlar FDA incelemesinden \u00f6nce veya sonra herhangi bir noktada g\u00f6n\u00fcll\u00fc olarak BLA&#039;y\u0131 geri \u00e7ekebilirler.<\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-question-1762183285301\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question\">BLA onay\u0131ndan sonra ne olur?<\/h3>\n<div class=\"rank-math-answer\">\n\n<p>\u00dcreticiler, pazarlama sonras\u0131 g\u00f6zetim, periyodik g\u00fcvenlik raporlamas\u0131 ve FDA taraf\u0131ndan zorunlu k\u0131l\u0131nan ek \u00e7al\u0131\u015fmalara uymak zorundad\u0131r.<\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\" id=\"conclusion\"><strong>Sonu\u00e7<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Biyolojik Lisans Ba\u015fvurusu (BLA), Amerika Birle\u015fik Devletleri&#039;ndeki biyolojik \u00fcr\u00fcnler i\u00e7in d\u00fczenleyici s\u00fcrecin temel ta\u015f\u0131d\u0131r. BLA yap\u0131s\u0131n\u0131, ba\u015fvuru gerekliliklerini ve inceleme s\u00fcrecini anlayan sponsorlar, FDA standartlar\u0131na uyumu sa\u011flarken pazara giri\u015f s\u00fcre\u00e7lerini kolayla\u015ft\u0131rabilirler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0130ster a\u015f\u0131, ister gen tedavisi, isterse monoklonal antikor geli\u015ftiriliyor olsun, BLA&#039;n\u0131n titizlikle haz\u0131rlanmas\u0131, d\u00fczenleyici ba\u015far\u0131 ile maliyetli gecikmeler aras\u0131ndaki fark\u0131 yaratabilir.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Devam\u0131n\u0131 oku<\/strong>:\u00a0<a href=\"https:\/\/dmdwarrior.com\/tr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Duchenne \u0130\u00e7in Klinik Ara\u015ft\u0131rmalar (T\u00fcm Ara\u015ft\u0131rmalar\u0131n Listesi)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><br><\/p>","protected":false},"excerpt":{"rendered":"<p>The Biologics License Application (BLA) plays a critical role in bringing new biologic therapies for Duchenne Muscular Dystrophy (DMD) to patients. A BLA is the formal submission that a biotechnology or pharmaceutical company makes to the U.S. Food and Drug Administration (FDA) to request approval for marketing a biologic product. In the context of Duchenne, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5030,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[128,88],"class_list":["post-5027","post","type-post","status-publish","format-standard","has-post-thumbnail","category-dmd","tag-bla","tag-fda"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=5027"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/5027\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/5030"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=5027"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=5027"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=5027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}